Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide. Pentetreotide is an indium-labelled somatostatin analog and can be uesd to nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis^[1][2]. In Vitro: Neuroendocrine tumors have an increased number of somatostatin receptors, as compared to normal tissues. At present time, there are five known subtypes. Somatostatin receptor scintigraphy with ¹¹¹In-Pentetreotide binds to two of these subtypes and is effective in visualizing neuroendocrine tumors, and its metastasis with an overall diagnostic sensitivity of 70% to 90%. It is considerably more sensitive than conventional anatomic imaging. Its usage in neuroendocrine tumors not only includes assessment of disease extent, but also in identified primary lesion, assesses treatment response, and selection for radionuclide therapy^[1].